Back To Search Instructions
Protocols
21 protocols meet the specified criteria
Disease Site: Any Site
Protocol No.TitleStatus
0300000620Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries (1991-0002)Open
0600000609Arizona Cancer Center Biospecimen RepositoryOpen
0800000473ACCRN07: Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)Open
1200000138Biospecimen Repository for Individuals at High Risk for Breast, Ovarian, or Other Hereditary CancersOpen
1200000177COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive MutationsOpen
1300000043Effects of Heavy Metal Exposure on DNA RepairOpen
1300000173Research Retention Strategies for Cancer Survivorship Studies: A Survey of Participant OpinionsOpen
1403269898Clinical study of the effect of combined treatment of aspirin and zileuton on biomarkers of tobacco-related carcinogenesis in current smokers Open
1502660379S1316: Prospective Comparative Effectiveness Trial for Malignant Bowel ObstructionOpen
1502661845A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the treatment of multiple Metastases (NRG-BR001)Open
1504814936AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing SarcomaOpen
1509106328ALTE11C2: Health Effects after Anthracycline and Radiation Therapy: Dexrazoxane and Prevention of Anthracycline-related CardiomyopathyOpen
1509136789ALTE05N1: Umbrella Long-Term Follow-Up ProtocolOpen
1605600303Isolation and Characterization of Circulating Tumor Cells (CTCs)Open
1606619215An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerOpen
1612049078A Phase I Multicenter, Open Label Study of Enadenotucirev Combined with PD-1 Inhibitor in Subjects with Metastatic or Advanced Epithelial TumorsOpen
1704390293A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsOpen
1705411350A Randomized Phase III Trial Of TRC105 And Pazopanib Versus Pazopanib Alone In Patients With Advanced Angiosarcoma (Tappas) Open
2002-0063Protocol for a Research Database For Hematopoieitc Stem Cell Transplantation and Marrow Toxic InjuriesOpen
25207Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients Open
PHXE-16-0073-80-15A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 (PD-1), AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES, IN PATIENTS WITH ADVANCED MALIGNANCIESOpen